Scinai Immunotherapeutics
SCNI
11 hedge funds and large institutions have $277K invested in Scinai Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
48% less capital invested
Capital invested by funds: $534K → $277K (-$258K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.98K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.21K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$894 |
| 4 |
Credit Agricole
Montrouge Cedex,
France
|
+$289 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$90.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$16.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $137K | -$90.5K | -13,155 | -36% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $131K | -$16.7K | -2,431 | -10% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $3.08K | +$1.21K | +176 | +50% |
|
|
4
Morgan Stanley
New York
| $3.08K | +$1.98K | +288 | +126% |
|
|
5
UBS Group
Zurich,
Switzerland
| $1.26K | +$894 | +130 | +159% |
|
|
6
Credit Agricole
Montrouge Cedex,
France
| $252 | +$289 | +42 | New |
|
|
MSG
7
Main Street Group
Glen Allen,
Virginia
| $119 | +$138 | +20 | New |
|
|
APC
8
Aspire Private Capital
Cornelius,
North Carolina
| $95 | – | – | – |
|
|
GRP
9
Global Retirement Partners
San Rafael,
California
| $29 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $12 | – | – | – |
|
11
Qube Research & Technologies (QRT)
London,
United Kingdom
| $4 | – | – | – |
|
SCNI Hedge Fund Activity: Q4 2023 in Review
11 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2023, worth a combined $277K — down 48% from $534K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SCNI positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.98K. The largest seller was Armistice Capital, cutting an estimated $90.5K.
- 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2023, up from 9 in Q3 2023.
- Funds reported $277K of Scinai Immunotherapeutics stock for Q4 2023, down 48% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $1.98K added.
- The largest Scinai Immunotherapeutics seller in Q4 2023 was Armistice Capital, an estimated $90.5K sold.
Based on aggregated 13F filings for Q4 2023.